GeoVax Announces $6 Million Public Offering to Advance Immunotherapy and Vaccine Development
TL;DR
GeoVax Labs, Inc. secures a $6 million public offering, offering investors a chance to buy shares and warrants at $0.65 per unit, potentially boosting their portfolio with a stake in innovative cancer and infectious disease treatments.
GeoVax Labs, Inc. announces a public offering of 9.2 million units at $0.65 each, including shares and warrants, with Roth Capital Partners facilitating the transaction, aiming to raise approximately $6 million for working capital and general corporate purposes.
GeoVax Labs, Inc.'s public funding initiative supports the development of vaccines and therapies for cancer and infectious diseases, contributing to global health improvements and potentially saving lives.
GeoVax Labs, Inc. is advancing its COVID-19 vaccine and cancer therapy trials, with a new public offering to fuel groundbreaking medical research and development.
Found this article helpful?
Share it with your network and spread the knowledge!
GeoVax Labs, Inc., a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases, has announced a public offering expected to raise approximately $6 million in gross proceeds. The offering involves the sale of about 9.2 million units, each consisting of one share of common stock and warrants to purchase additional shares, priced at $0.65 per unit. This strategic move is aimed at bolstering the company's working capital and supporting general corporate purposes, with Roth Capital Partners serving as the exclusive placement agent for the offering.
The warrants included in the offering grant the right to purchase up to approximately 18.5 million shares of common stock at an exercise price of $0.65 per share, exercisable immediately and valid for five years. The closing of the offering is anticipated around July 2, 2025, pending the fulfillment of standard closing conditions. This financial infusion is pivotal for GeoVax as it continues to advance its clinical programs, including GEO-CM04S1, a next-generation COVID-19 vaccine, and Gedeptin®, an oncolytic solid tumor gene-directed therapy.
GeoVax's commitment to addressing unmet medical needs through innovative vaccines and therapies is underscored by this offering. The company's portfolio, which also includes a vaccine targeting Mpox and smallpox, is poised for significant advancements, with a Phase 3 clinical evaluation for the Mpox vaccine on the horizon. The successful completion of this offering could accelerate the development and potential commercialization of these critical healthcare solutions, offering hope to patients worldwide.
For further details on the offering, interested parties can access the prospectus supplement and accompanying prospectus on the SEC's website. This announcement represents a forward-looking statement, subject to risks and uncertainties that could affect the company's plans and outcomes. GeoVax's progress in clinical trials and regulatory approvals will be key factors in realizing the potential of its innovative therapies and vaccines.
Curated from NewMediaWire
